Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review

Eliza W Beal, Ohio State University
Lorena P Suarez-Kelly, Ohio State University
Charles W Kimbrough, Ohio State University
Fabian M Johnston, Johns Hopkins University
Jonathan Greer, Johns Hopkins University
Daniel E Abbott, University of Wisconsin, Madison
Courtney Pokrzywa, University of Wisconsin, Madison
Mustafa Raoof, City of Hope National Medical Center
Byrne Lee, City of Hope National Medical Center
Travis E Grotz, Mayo Clinic

Only first 10 authors above; see publication for full author list.

Journal Title: JOURNAL OF CLINICAL MEDICINE
Volume: Volume 9, Number 3
Publisher: MDPI | 2020-03-01
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.3390/jcm9030748
Permanent URL: https://pid.emory.edu/ark:/25593/vzzm5

Final published version: http://dx.doi.org/10.3390/jcm9030748

Copyright information:
© 2020 by the authors.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/rdf).
Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review

Eliza W. Beal 1,4, Lorena P. Suarez-Kelly 1,†, Charles W. Kimbrough 1, Fabian M. Johnston 2, Jonathan Greer 2, Daniel E. Abbott 3, Courtney Pokrzywa 3, Mustafa Raoof 4, Byrne Lee 4, Travis E. Grotz 5, Jennifer L. Leiting 5, Keith Fournier 6, Andrew J. Lee 6, Sean P. Dineen 7, Benjamin Powers 7, Jula Veerapong 8, Joel M. Baumgartner 8, Callisia Clarke 9, Harveshp Mogal 9, Marti C. Russell 10, Mohammed Y. Zaidi 10, Sameer H. Patel 11, Vikrom Dhar 11, Laura Lambert 12, Ryan J. Hendrix 12, John Hays 1, Sherif Abdel-Misih 1 and Jordan M. Cloyd 1,*

1 Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH 43201, USA; Eliza.Beal@osumc.edu (E.W.B.); Lorena.Suarez-Kelly@prevea.com (L.P.S.-K); Charles.Kimbrough@bswhealth.org (C.W.K.); John.Hays@osumc.edu (J.H.); Sherif.Abdel-Misih@stonybrookmedicine.edu (S.A.-M.)
2 Department of Surgery, Division of Surgical Oncology, Johns Hopkins University, Baltimore, MD 21205, USA; fjohnst4@jhmi.edu (F.M.J.); jgreer13@jhmi.edu (J.G.)
3 Department of Surgery, Division of Surgical Oncology, University of Wisconsin, Madison, WI 53792, USA; abbott@surgery.wisc.edu (D.E.A.); cpokrzywa@wisc.edu (C.P.)
4 Department of Surgery, Division of Surgical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA; mraoof@coh.org (M.R.); bleece@coh.org (B.L.)
5 Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN 55905, USA; grotz.travis@mayo.edu (T.E.G.); leiting.jennifer@mayo.edu (J.L.L.)
6 Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 44907, USA; kfourni@mdanderson.org (K.F.); andyjoonlee@gmail.com (A.J.L.)
7 Department of Gastrointestinal Surgery, Moffitt Cancer Center, Tampa, FL 33612, USA; Sean.Dineen@moffitt.org (S.P.D.); Benjamin.Powers@moffitt.org (B.P.)
8 Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, CA 92093, USA; jveerapong@ucsd.edu (J.V.); jlbbaumgartner@ucsd.edu (J.M.B.)
9 Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; cnclarke@mcw.edu (C.C.); hmogal@mcw.edu (H.M.)
10 Winship Cancer Institute, Division of Surgical Oncology, Emory University, Atlanta, GA 30322, USA; mrussell@emory.edu (M.C.R.); mzaidi@emory.edu (M.Y.Z.)
11 Department of Surgery, University of Cincinnati, Cincinnati, OH 45219, USA; patel5se.ucmail.uc.edu (S.H.P.); dhavrk@ucmail.uc.edu (V.D.)
12 Department of Surgery, Division of Surgical Oncology, University of Massachusetts Memorial Medical Center, Worcester, MA 45219, USA; laura.lambert@hci.utah.edu (L.L.); ryan.hendrix@umassmemorial.org (R.J.H.)
* Correspondence: Jordan.Cloyd@osumc.edu; Tel.:+1-614-293-4583
† These authors have contributed equally to this work.

Received: 14 January 2020; Accepted: 4 March 2020; Published: 10 March 2020

Abstract: Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved survival for patients with colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant chemotherapy (NAC) prior to CRS-HIPEC is poorly understood. A retrospective review of adult patients with CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 patients who underwent CRS+/-HIPEC, 196 (65.8%)
received NAC while 102 (34.2%) underwent surgery first (SF). Patients who received NAC had lower peritoneal cancer index score (12.1 ± 7.9 vs. 14.3 ± 8.5, \( p = 0.034 \)). There was no significant difference in grade III/IV complications (22.4% vs. 16.7%, \( p = 0.650 \)), readmission (32.3% vs. 23.5%, \( p = 0.114 \)), or 30-day mortality (1.5% vs. 2.9%, \( p = 0.411 \)) between groups. NAC patients experienced longer overall survival (OS) (median 32.7 vs. 22.0 months, \( p = 0.044 \)) but similar recurrence-free survival (RFS) (median 13.8 vs. 13.0 months, \( p = 0.456 \)). After controlling for confounding factors, NAC was not independently associated with improved OS (OR 0.80) or RFS (OR 1.04). Among patients who underwent CRS+/HIPEC for CR-PM, the use of NAC was associated with improved OS that did not persist on multivariable analysis. However, NAC prior to CRS+/HIPEC was a safe and feasible strategy for CR-PM, which may aid in the appropriate selection of patients for aggressive cytoreductive surgery.

**Keywords:** cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; colorectal peritoneal metastases

### 1. Introduction

There are over 1.8 million cases of colorectal cancer (CRC) diagnosed annually and 881,000 annual deaths from CRC, ranking it third in incidence and second in mortality worldwide [1]. Approximately 17% of patients with metastatic CRC have peritoneal metastases (CR-PM), while 2% have the peritoneum as the only site of metastatic disease [2,3]. It has long been known that peritoneal involvement by CRC is a poor prognostic factor as these patients have shorter progression-free and overall survival (OS) compared to patients with other types of metastatic CRC [4–6]. In a recent meta-analysis of 14 randomized controlled trials including 10,553 patients with metastatic CRC, OS was better among patients with isolated nonperitoneal sites of metastases than in those with isolated CR-PM [3]. Among patients with several sites of metastases, peritoneal involvement was an independently poor prognostic feature [3].

Historically, CR-PM was considered a terminal condition, associated with a short survival duration and poor quality of life, and was treated with palliative chemotherapy alone. However, as is observed for patients with isolated liver or pulmonary metastases, surgical resection of isolated CR-PM has been found to be associated with survival benefits in appropriately selected patients. Indeed, multiple retrospective series and a few randomized controlled trials have found that cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with good long-term survival rates among well-selected patients with CR-PM [2,7–14].

The role of neoadjuvant chemotherapy (NAC) prior to surgery for resectable CR-PM is currently debated, and previous literature on the subject is mixed [7,15–17]. Proponents of NAC argue that NAC offers early systemic treatment and improves selection of patients for surgery [18]. On the other hand, NAC may lead to worsened patient physical condition or result in a missed window for surgery [19]. These considerations are similar to the current discussion surrounding the treatment of isolated colorectal liver metastases [20,21]. Furthermore, current guidelines suggest that the use of NAC or proceeding straight to surgery are acceptable alternatives [2]. Given this controversy, we set out to explore the impact of NAC on the short- and long-term outcomes of patients with isolated CR-PM using a multi-institutional dataset.

### 2. Experimental Section

A retrospective review of adult patients with colorectal peritoneal metastases (CR-PM) who underwent cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) at 12 U.S. institutions from 2000–2017 was performed using the United States Hyperthermic Intraperitoneal Chemotherapy (US HIPEC) Collaborative. The database included all patients treated...
with CRS ± HIPEC between 1 January 2000 and 1 September 2017. Data were collected at each institution using a standardized data collection sheet. Patients were included in the study if their primary site of disease was adenocarcinoma of the colon or rectum. Patients with extraperitoneal disease were excluded as were those with primary CRC and a peritoneal carcinomatosis index (PCI) score of zero (i.e., prophylactic HIPEC). Institutional review board approval was obtained at the primary, and each additional, site prior to the initiation of data collection.

Preoperative demographic and clinical information was retrospectively recorded for each patient who underwent CRS ± HIPEC. For the purpose of this study, NAC was defined as systemic chemotherapy administered to patients with a diagnosis of CR-PM who subsequently underwent CRS ± HIPEC. Patients who received systemic therapy with neoadjuvant intent but ultimately did not undergo surgery were not included. Intraoperative data recorded included procedures performed, operative time, intraoperative fluid administration, estimated blood loss, PCI score, and completeness of cytoreduction (CC) score. The PCI score grades the extent of peritoneal dissemination on a continuous scale ranging from 0–39. The CC score is used to define the completeness of cytoreduction where CC-0 indicates no visible disease remaining, CC-1 indicates nodules less than 2.5 mm persisting after cytoreduction, CC-2 indicates nodules between 2.5 mm and 5.0 cm, and CC-3 suggests nodules greater than 5 cm [22]. Postoperative outcomes including complications, length of stay, and readmissions were recorded. Complications were classified according to the Clavien–Dindo system. Grade I complications include any minor deviation from the planned postoperative course. Grade II complications require pharmacologic management. Grade III complications require interventions performed under local or general anesthesia. Grade IV complications include those that threaten patient life with single- or multiorgan failure. Grade V complications are those that result in patient death [23]. Long-term outcomes, including overall survival (OS) and recurrence-free survival (RFS), were recorded. OS was defined as time from the date of surgery until death or last follow-up. RFS was defined as time from the date of surgery until clinical or radiographic evidence of recurrence or disease progression on last follow-up.

Patients were divided into two groups—those who received neoadjuvant chemotherapy followed by surgery (NAC group) and those who underwent surgery first (SF). Demographic and clinical characteristics were directly compared between the two groups. Differences between groups were assessed using chi-square tests for categorical variables and Kruskal–Wallis one-way analysis of variance for continuous variables. The short- and long-term outcomes of patients in the NAC group and SF group were directly compared. Kaplan–Meier and univariate and multivariable Cox regression analysis were used to analyze RFS and OS. Factors with \( p \)-value < 0.1 on univariate analysis as well as the receipt of NAC were included in multivariable analysis.

Two sets of supplemental analyses were performed. The first compared patients who received NAC with bevacizumab versus those who underwent SF. The second examined patients with high-grade tumors (poorly differentiated and/or signet ring cell histologies) who received NAC compared to those with high-grade tumors who underwent SF. For each, Kaplan–Meier and univariate and multivariable Cox regression analysis were used to analyze OS and RFS. For all analyses, STATA 14.2 MP (College Station, TX) was used, and statistical significance set as \( p < 0.05 \).

3. Results

Among 298 patients with isolated CR-PM who met inclusion criteria and underwent CRS ± HIPEC, 196 (66%) received NAC while 102 (34%) underwent SF. Patient demographics and perioperative characteristics are reported in Table 1. In the entire cohort, the mean age was 54.1 years and 54% were female. The majority of patients were American Society of Anesthesiology (ASA) Class III (223, 81%) with an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 (140, 59%). There were no significant differences between the two groups in regards to age, gender, ASA class, performance status, most comorbidities, tobacco use, disease-related symptoms, or synchronous peritoneal disease. In the NAC group, 31% of patients had poor tumor differentiation and/or signet
ring cells, compared to 17% in the SF group \((p = 0.087)\). The chemotherapy regimens used in this cohort varied considerably but were all commonly used regimens for colorectal cancer (Table 2). Fifty-four percent of patients who underwent NAC received bevacizumab.

### Table 1. Patient Characteristics \((N = 298)\).

|                            | All Patients | NAC | SF | \(p\)-Value * |
|---------------------------|--------------|-----|----|---------------|
| N                         | 298          | 196 | 102|               |
| Follow-up (months), mean ± SD (range) | 18.6 ± 18.7 (0.2–124) | 19.2 ± 20.1 (0.3–124) | 17.3 ± 16.1 (0.2–70.8) | 0.372 |
| Age (years), mean ± SD (range) | 54.1 ± 12.9 (20–95) | 53.2 ± 12.5 (22–78) | 55.8 ± 13.7 (20–95) | 0.121 |
| BMI | 27.7 ± 6.0 (17.3–60.7) | 27.3 ± 6.2 (17.3–60.7) | 28.6 ± 5.6 (18.9–43.8) | 0.084 |
| Female | 161 | 104 | 57 | 0.643 |
| ASA Class | | | | |
| I | 0 | 0% | 0 | 0% | 0.065 |
| II | 31 | 11% | 17 | 10% | |
| III | 223 | 81% | 150 | 85% | |
| IV | 22 | 8% | 10 | 6% | 2% |
| ECOG Performance Status | | | | |
| 0 | 140 | 59% | 83 | 57% | 57 | 63% | 0.372 |
| 1 | 84 | 36% | 54 | 37% | 30 | 33% | 0.432 |
| 2 | 11 | 5% | 8 | 3% | 3 | 3% | |
| 3 | 1 | 0% | 8 | 3% | 3 | 3% | |
| Comorbidities | | | | |
| Hypertension | 100 | 36% | 59 | 59% | 41 | 41% | 0.178 |
| Diabetes | 23 | 8% | 17 | 8% | 9 | 9% | 0.729 |
| CHF | 8 | 3% | 7 | 4% | 1 | 1% | 0.163 |
| Prior cardiac event | 16 | 6% | 9 | 5% | 7 | 7% | 0.496 |
| Prior CVA | 5 | 2% | 4 | 2% | 1 | 1% | 0.499 |
| COPD | 3 | 1% | 0 | 0% | 3 | 3% | 0.020 |
| CKD | 5 | 2% | 4 | 2% | 1 | 1% | 0.683 |
| PVD | 13 | 5% | 13 | 7% | 0 | 0% | 0.007 |
| Asciites | 20 | 7% | 11 | 6% | 9 | 9% | 0.374 |
| Systemic Anticoagulation | 21 | 7% | 17 | 9% | 4 | 4% | 0.128 |
| Chronic Steroid Use | 5 | 2% | 5 | 3% | 0 | 0% | 0.092 |
| Rheumatic disease | 6 | 2% | 4 | 2% | 2 | 2% | 0.963 |
| Tobacco use | | | | |
| Current | 23 | 8% | 17 | 10% | 6 | 6% | 0.550 |
| Former | 68 | 24% | 44 | 25% | 24 | 24% | |
| Symptomatic | | | | |
| GI Bleed | 15 | 5% | 10 | 5% | 5 | 5% | 0.933 |
| Obstruction | 15 | 5% | 11 | 6% | 4 | 4% | 0.515 |
| Diarrhea | 6 | 2% | 3 | 2% | 3 | 3% | 0.464 |
| Constipation | 14 | 5% | 11 | 6% | 3 | 3% | 0.281 |
| Pain | 73 | 26% | 48 | 27% | 25 | 25% | 0.706 |
| Nausea/Vomiting | 11 | 4% | 8 | 3% | 3 | 3% | 0.541 |
| Anorexia | 8 | 3% | 7 | 4% | 1 | 1% | 0.161 |
| Fatigue | 29 | 10% | 18 | 10% | 11 | 11% | 0.792 |
| Anemia | 37 | 14% | 21 | 12% | 16 | 17% | 0.246 |
| GERD/Dyspepsia | 40 | 15% | 35 | 20% | 5 | 5% | 0.001 |
| Synchronous peritoneal disease | 107 | 36% | 73 | 37% | 34 | 33% | 0.196 |
| Previous cytoreduction | 49 | 16% | 29 | 15% | 20 | 20% | 0.288 |
| Previous HIPEC | 12 | 4% | 3 | 1% | 9 | 3% | 0.002 |
| Tumor Differentiation—Poor and/or Signet Ring Cell | 77 | 26% | 60 | 31% | 17 | 18% | 0.087 |

* \(p\)-Values are for comparison of NAC and SF group. NAC, Neoadjuvant Chemotherapy; SF, Surgery First; BMI, Body Mass Index; ASA, American Society of Anesthesiology; ECOG, Eastern Cooperative Oncology Group; CHF, Congestive Heart Failure; CVA, Cerebrovascular Accident; COPD, Chronic Obstructive Pulmonary Disease; CKD, Chronic Kidney Disease; PVD, Peripheral Vascular Disease; GI, Gastrointestinal; GERD, Gastroesophageal Reflux Disease; HIPEC, hyperthermic intraperitoneal chemotherapy.
Table 2. Neoadjuvant Chemotherapy Regimens.

| Regimen                        | n   | %    |
|--------------------------------|-----|------|
| FOLFIRI + Bevacizumab          | 45  | 23.0%|
| FOLFOX + Bevacizumab           | 42  | 21.4%|
| FOLFOX                         | 37  | 18.9%|
| FOLFIRI                        | 20  | 10.2%|
| Xeloda + Bevacizumab           | 9   | 4.6% |
| FOLFOXIRI + Bevacizumab        | 5   | 2.6% |
| 5FU ± Leucovorin               | 3   | 1.5% |
| Xeloda                         | 3   | 1.5% |
| XELOX                          | 3   | 1.5% |
| XELOX + Bevacizumab            | 2   | 1.0% |
| Other                          | 24  | 12.3%|
| Other + Bevacizumab            | 3   | 1.5% |

Patients who received NAC had a lower mean PCI score (12.1 + 7.9 vs. 14.3 + 8.5, p = 0.034) and shorter operative time (7.7 + 2.9 vs. 8.7 + 2.7 h, p = 0.013), but no difference in rates of CC-0 (74% vs. 66%, p = 0.14) compared to the SF group (Table 3). There were no significant differences in rates of 30-day overall complications (61% vs. 60%, p = 0.672), grade III/IV complications (22% vs. 17%, p = 0.650), hospital readmissions (32% vs. 24%, p = 0.114), or 30-day mortality (2% vs. 3%, p = 0.411) among patients in the NAC and SF groups, respectively.

Table 3. Tumor and Operative Characteristics.

|                      | All Patients | NAC | SF | p-Value * |
|----------------------|--------------|-----|----|-----------|
| PCI, mean ± SD (range)| 12.9 ± 8.2 (1–39) | 12.1 ± 7.9 (1–38) | 14.3 ± 8.5 (2–39) | 0.034 |
| CCR                  |              |     |    | 0.218     |
| 0                    | 212          | 145 | 67 |           |
| 1                    | 49           | 31  | 18 |           |
| ≥ 2                  | 37           | 20  | 17 |           |
| HIPEC                |              |     |    | 0.204     |
| 95.9%                | 281          | 190 | 91 |           |
| Chemotherapy         |              |     |    | 0.822     |
| Mitomycin C          | 273          | 184 | 89 |           |
| Oxaliplatin          | 7            | 5   | 2  |           |
| HIPEC Infusion Time  |              |     |    | 0.364     |
| (minutes), mean ± SD (range) | 88.0 ± 9.7 | 88.4 ± 9.1 | 87.2 ± 10.7 |           |
| Operative Time       | 7.8 ± 2.9 (0–20.8) | 7.7 ± 2.9 (0–20.8) | 8.7 ± 2.7 (2.5–14.5) | 0.013 |
| EBL (mL), mean ± SD (range) | 437.4 ± 641.5 | 447.0 ± 740.9 | 419.1 ± 388.9 | 0.672 |
| Any postoperative complication | 180 | 60.40% | 119 | 60.70% | 61 | 59.80% | 0.879 |
| Highest Clavien–Dindo grade | I | 20 | 10.90% | 11 | 9.00% | 9 | 14.50% |
| II                   | 98           | 64  | 34 | 54.80%   |
| III                  | 46           | 34  | 12 | 19.40%   |
| IV                   | 15           | 10  | 5  | 8.10%    |
| V                    | 5            | 3   | 2  | 3.20%    |
| Hospital LOS (days)  | 12.1 ± 8.0 (0–68) | 12.2 ± 8.2 (3–68) | 12.1 ± 7.7 (0–49) | 0.974 |
| Adjuvant chemotherapy | 78           | 62  | 16 | 33.30%   |
| Neoadjuvant Radiation | 8            | 8   | 0  | 0%       |
| Adjuvant Radiation   | 7            | 5   | 2  | 4.90%    |

* p-Values are for comparison of NAC and SF groups. NAC, Neoadjuvant Chemotherapy; SF, Surgery First; PCI, peritoneal carcinomatosis index; CCR, Completeness of Reduction Score; HIPEC, Hyperthermic Intraperitoneal Chemotherapy; EBL, Estimated Blood Loss; LOS, Length of Stay.
Patients who received NAC prior to CRS +/- HIPEC experienced a longer OS (Figure 1A, median 32.7 vs. 22.0 months, \( p = 0.044 \)) but similar RFS (Figure 1B, median 13.8 vs. 13.0 months, \( p = 0.456 \)) compared to those who underwent SF. The results of univariate and multivariable cox regression analysis for OS and RFS are reported in Tables 4 and 5, respectively. After controlling for confounding factors, NAC was not independently associated with improved OS (OR 0.80, 95% CI 0.54–1.17) or RFS (OR 1.04, 95% CI 0.74–1.47). On multivariable Cox regression analysis, increasing PCI score (OR 1.05, 95% CI 1.03–1.08), incomplete cytoreduction (CC-1: OR 2.18, 95% CI 1.31–3.63; CC-2/3: OR 2.37, 95% CI 1.21–4.67), and synchronous CR-PM (OR 0.63, 95% CI 0.42–0.94) were significantly associated with OS (Table 4). Only increasing PCI score (OR 1.05, 95% CI 1.02–1.07) was found to be independently associated with RFS (Table 5).

On subset analysis comparing patients who underwent NAC with bevacizumab (\( n = 105, 51\% \)) to those who underwent SF (\( n = 102, 49\% \)), there was no difference in the proportion of patients who experienced any perioperative complication (\( p = 0.912 \)). Receipt of NAC + bevacizumab was not a significant predictor of OS (Figure 2A, \( p = 0.349 \)) or RFS (Figure 2B, \( p = 0.410 \)) on Kaplan–Meier analysis. Additionally, receipt of NAC + bevacizumab was not a significant predictor of OS (\( p = 0.449 \)) or RFS (\( p = 0.153 \)) on multivariable Cox proportional hazard models (data not shown). On subset analysis of patients with high-grade tumors (poorly differentiated and/or signet ring cells) comparing those who received NAC (56, 61%) to those who underwent SF (36, 39%), receipt of NAC was not a significant predictor of OS (Figure 2C, \( p = 0.243 \)) or RFS (Figure 2D, \( p = 0.362 \)) on Kaplan–Meier analysis. Receipt of NAC was also not a significant predictor of OS (\( p = 0.084 \)) or RFS (\( p = 0.480 \)) on multivariable Cox proportional hazard models (data not shown). This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation as well as the experimental conclusions that can be drawn.

![Figure 1](image-url). Kaplan–Meier Survival Analysis for (A) Overall Survival and (B) Recurrence-Free Survival among patients with CR-PM undergoing CRS ± HIPEC.
Table 4. Univariate and Multivariable Cox Regression Analysis for Overall Survival.

|                          | Univariate          |          | Multivariable       |          |
|--------------------------|---------------------|----------|---------------------|----------|
|                          | HR (95% CI)         | p-Value  | HR (95% CI)         | p-Value  |
| Gender                   |                     |          |                     |          |
| Female                   | Ref                 |          | Ref                 |          |
| Male                     | 1.19 (0.83, 1.70)   | 0.344    |                     |          |
| Age (years)              | 1.00 (0.98, 1.01)   | 0.748    |                     |          |
| BMI                      | 0.97 (0.94, 1.01)   | 0.104    |                     |          |
| ASA Class                |                     |          |                     |          |
| II                       | Ref                 |          | Ref                 |          |
| III                      | 1.52 (0.79, 2.94)   | 0.209    |                     |          |
| IV                       | 1.36 (0.58, 3.22)   | 0.478    |                     |          |
| Previous HIPEC           |                     |          |                     |          |
| No                       | Ref                 |          | Ref                 |          |
| Yes                      | 1.95 (0.91, 4.19)   | 0.088    | 1.46 (0.62, 3.43)   | 0.384    |
| Symptomatic              |                     |          |                     |          |
| No                       | Ref                 |          | Ref                 |          |
| Yes                      | 1.30 (0.91, 1.87)   | 0.143    |                     |          |
| Synchronous Peritoneal Disease |                 |          |                     |          |
| No                       | Ref                 |          | Ref                 |          |
| Yes                      |                     |          | Ref                 |          |
| PCI Score                | 1.07 (1.05, 1.10)   | < 0.001  | 1.05 (1.03, 1.08)   | < 0.001  |
| CCR                      |                     |          |                     |          |
| 0                        | Ref                 |          | Ref                 |          |
| 1                        | 3.56 (2.29, 5.52)   | < 0.001  | 2.18 (1.31, 3.63)   | 0.003    |
| ≥ 2                      | 4.59 (2.78, 7.57)   | < 0.001  | 2.37 (1.21, 4.67)   | 0.012    |
| HIPEC                    |                     |          |                     |          |
| No                       | Ref                 |          | Ref                 |          |
| Yes                      | 0.33 (0.16, 0.68)   | 0.003    | 0.57 (0.24, 1.36)   | 0.204    |
| Tumor Differentiation    |                     |          |                     |          |
| Well Differentiated      | Ref                 |          | Ref                 |          |
| Moderately Differentiated| 1.35 (0.63, 2.87)   | 0.442    |                     |          |
| Poorly Differentiated    | 1.40 (0.64, 3.06)   | 0.402    |                     |          |
| Not Reported             | 1.35 (0.63, 2.89)   | 0.435    |                     |          |
| Any postoperative complication |                 |          |                     |          |
| No                       | Ref                 |          | Ref                 |          |
| Yes                      | 1.24 (0.86, 1.79)   | 0.251    |                     |          |
| Neoadjuvant Chemotherapy |                     |          |                     |          |
| No                       | Ref                 |          | Ref                 |          |
| Yes                      | 0.69 (0.48, 0.99)   | 0.045    | 0.80 (0.54, 1.17)   | 0.247    |
| Adjuvant Chemotherapy    |                     |          |                     |          |
| No                       | Ref                 |          | Ref                 |          |
| Yes                      | 1.00 (0.63, 1.58)   | 0.998    |                     |          |
| Neoadjuvant Radiation    |                     |          |                     |          |
| No                       | Ref                 |          | Ref                 |          |
| Yes                      | 1.65 (0.60, 4.53)   | 0.331    |                     |          |
| Adjuvant Radiation       |                     |          |                     |          |
| No                       | Ref                 |          | Ref                 |          |
| Yes                      | 0.77 (0.27, 2.16)   | 0.613    |                     |          |
Table 5. Univariate and Multivariable Cox Regression Analysis for Recurrence Free Survival.

|                                | Univariate                  |          |          | Multivariable                |          |          |
|--------------------------------|-----------------------------|----------|----------|-----------------------------|----------|----------|
|                                | HR (95% CI) | p-Value | HR (95% CI) | p-Value          |          |          |
| Gender                         |              |          |              |                  |          |          |
| Female                         | Ref          | Ref      | Ref          | Ref              |          |          |
| Male                           | 0.99 (0.73, 1.36) | 0.963    |              |                  |          |          |
| Age (years)                    | 1.00 (0.99, 1.01) | 0.943    |              |                  |          |          |
| BMI                            | 0.99 (0.96, 1.02) | 0.990    |              |                  |          |          |
| ASA Class                      |              |          |              |                  |          |          |
| II                             | Ref          | Ref      | Ref          | Ref              |          |          |
| III                            | 1.56 (0.90, 2.73) | 0.116    | 1.60 (0.90, 2.83) | 0.107 |          |          |
| IV                             | 2.03 (0.99, 4.17) | 0.054    | 1.90 (0.91, 3.98) | 0.089 |          |          |
| Previous HIPEC                 |              |          |              |                  |          |          |
| No                             | Ref          | Ref      | Ref          | Ref              |          |          |
| Yes                            | 1.52 (0.75, 3.11) | 0.249    |              |                  |          |          |
| Symptomatic                    |              |          |              |                  |          |          |
| No                             | Ref          | Ref      | Ref          | Ref              |          |          |
| Yes                            | 0.72 (0.52, 1.00) | 0.041    | 0.80 (0.56, 1.14) | 0.213 |          |          |
| Synchronous Peritoneal Disease |              |          |              |                  |          |          |
| No                             | Ref          | Ref      | Ref          | Ref              |          |          |
| Yes                            | 0.90 (0.65, 1.24) | 0.507    |              |                  |          |          |
| PCI Score                      | 1.04 (1.03, 1.07) | < 0.001  | 1.05 (1.02, 1.07) | < 0.001 |          |          |
| CCR                            |              |          |              |                  |          |          |
| 0                              | Ref          | Ref      | Ref          | Ref              |          |          |
| 1                              | 1.52 (1.02, 2.29) | 0.041    | 0.74 (0.45, 1.22) | 0.242 |          |          |
| ≥ 2                            | 0.82 (0.41, 1.61) | 0.557    | 0.57 (0.26, 1.27) | 0.172 |          |          |
| HIPEC                           |              |          |              |                  |          |          |
| No                             | Ref          | Ref      | Ref          | Ref              |          |          |
| Yes                            | 0.59 (0.22, 1.61) | 0.506    |              |                  |          |          |
| Tumor Differentiation          |              |          |              |                  |          |          |
| Well Differentiated            | Ref          | Ref      | Ref          | Ref              |          |          |
| Moderately Differentiated      | 1.13 (0.62, 2.06) | 0.701    |              |                  |          |          |
| Poorly Differentiated          | 1.26 (0.68, 2.34) | 0.457    |              |                  |          |          |
| Not Reported                   | 0.64 (0.34, 1.21) | 0.173    |              |                  |          |          |
| Any postoperative complication |              |          |              |                  |          |          |
| No                             | Ref          | Ref      | Ref          | Ref              |          |          |
| Yes                            | 1.51 (1.09, 2.10) | 0.014    | 1.37 (0.74, 1.47) | 0.091 |          |          |
| Neoadjuvant Chemotherapy       |              |          |              |                  |          |          |
| No                             | Ref          | Ref      | Ref          | Ref              |          |          |
| Yes                            | 0.89 (0.64, 1.22) | 0.458    | 1.04 (0.74, 1.47) | 0.834 |          |          |
| Adjuvant Chemotherapy          |              |          |              |                  |          |          |
| No                             | Ref          | Ref      | Ref          | Ref              |          |          |
| Yes                            | 1.01 (0.70, 1.46) | 0.955    |              |                  |          |          |
| Neoadjuvant Radiation          |              |          |              |                  |          |          |
| No                             | Ref          | Ref      | Ref          | Ref              |          |          |
| Yes                            | 2.13 (0.86, 5.27) | 0.101    |              |                  |          |          |
| Adjuvant Radiation             |              |          |              |                  |          |          |
| No                             | Ref          | Ref      | Ref          | Ref              |          |          |
| Yes                            | 0.67 (0.27, 1.66) | 0.388    |              |                  |          |          |
or RFS (p = 0.153) on multivariable Cox proportional hazard models (data not shown). On subset analysis of patients with high-grade tumors (poorly differentiated and/or signet ring cells) comparing those who received NAC (56, 61%) to those who underwent SF (36, 39%), receipt of NAC was not a significant predictor of OS (Figure 2C, p = 0.243) or RFS (Figure 2D, p = 0.362) on Kaplan–Meier analysis. Receipt of NAC was also not a significant predictor of OS (p = 0.084) or RFS (p = 0.480) on multivariable Cox proportional hazard models (data not shown). This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation as well as the experimental conclusions that can be drawn.

4. Discussion

The current study is a large, multi-institutional, retrospective analysis of patients who underwent CRS ± HIPEC. This study was conducted to evaluate the impact of NAC on the short- and long-term outcomes of patients with isolated CR-PM. While patients who received NAC experienced a longer OS compared to those who underwent SF, NAC was not independently associated with improved RFS or OS after controlling for confounding factors. Nevertheless, NAC prior to CRS ± HIPEC appears to be safe and may assist with appropriate selection of patients for aggressive cytoreductive procedures.

The optimal multidisciplinary management of CR-PM continues to be debated [2]. Historically, peritoneal carcinomatosis from metastatic CRC was considered a terminal condition, treated only with palliative chemotherapy. While most patients with CR-PM are still treated with systemic chemotherapy alone, this approach has limited effectiveness due to pharmacokinetic limitations, poor peritoneal penetration, and impaired local drug distribution [4–6,24]. CRS-HIPEC has emerged as a locoregional therapy that is associated with improved survival outcomes among well-selected patients treated at experienced centers [7–14]. The recent PRODIGE 7 trial demonstrated impressive median OS of 41 to 42 months in patients treated with CRS +/- HIPEC [25]. Nevertheless, given the challenges in patient selection and the high locoregional and distant recurrence rates following successful surgery, the role of NAC prior to CRS ± HIPEC remains to be defined [15–17].

For patients with CR-PM, NAC may be recommended to prioritize systemic treatment and to optimize patient selection for an aggressive loco-regional operation. This approach aims to avoid CRS-HIPEC in patients with rapid disease progression during NAC and improve survival following...
completion of NAC and CRS-HIPEC. Nevertheless, prior literature on the use of NAC for CR-PM is mixed. Devilee et al., in a retrospective study examining patients with synchronous CR-PM undergoing CRS + HIPEC, reported that receipt of NAC was independently associated with improved OS [26]. In a retrospective review of patients with CR-PM, Passot et al. demonstrated an improvement in OS with NAC on univariate analysis that did not persist on multivariable analysis, similar to the current study [16]. Ceelen et al. demonstrated improvement in OS only when bevacizumab was included in the NAC regimen, a finding that was not replicated in our study [18]. On the other hand, two studies reporting on an overlapping data set demonstrated that the use of NAC was associated with decreased OS [17,27]. Waite et al. performed a systematic review and meta-analysis designed to assess the effect of neoadjuvant and adjuvant chemotherapy on the OS of patients undergoing CRS-HIPEC. Based on seven studies that met inclusion criteria, they concluded that the role of NAC could not be determined by the current evidence [15]. A multicenter Dutch randomized controlled trial is currently underway to test the role of NAC prior to CRS-HIPEC for CR-PM [28].

In addition to its importance for patient selection and early systemic treatment, NAC may be recommended for patients with significant disease burden with the intent of downstaging their disease and improving the odds of complete cytoreduction. Given that incomplete cytoreduction does not improve patient survival, the use of neoadjuvant strategies to increase the odds of obtaining CC0 is naturally appealing. However, the ability of NAC to downstage CR-PM prior to CRS-HIPEC is not well understood [7,11,26,29,30]. The current study demonstrates that patients who received NAC prior to CRS ± HIPEC for CR-PM had lower operative PCI scores compared to those who underwent SF. Whether this is an effect of the NAC or represents biological or selection differences between the two groups is impossible to know via the current study methodology. Therefore, the ability of NAC to downstage disease burden and facilitate complete cytoreduction warrants further investigation via prospective trials.

Although the role of NAC in optimizing long-term outcomes of CRS ± HIPEC remains controversial, the current study suggests its relative safety. While the current study was unable to capture toxicities experienced during NAC itself, both groups of patients had similar performance status and preoperative albumin levels, suggesting that NAC did not significantly lead to physical deconditioning of patients at the time of surgery. Furthermore, it is notable that in this study, there was no significant difference in overall complication rates or in Clavien–Dindo grade III/IV complication rates between patients who received NAC versus those who underwent SF. The Prodigie 7 trial, in which the majority of patients had received NAC, demonstrated a relatively low postoperative mortality (1.5%) and 60-day grade III-IV morbidity (13.6%–24.1%) [25]. Similarly, a recent trial examining the use of NAC in patients with ovarian cancer undergoing CRS-HIPEC reported relatively low rates of postoperative complications [31].

Although the current study did not find a significant association between NAC and OS on multivariable analysis, the identified factors associated with OS are consistent with the findings of previous studies. PCI score and completeness of cytoreduction are two of the most important, and reproducibly shown, prognostic factors associated with outcomes of patients undergoing CRS ± HIPEC [7,14]. The finding that synchronous disease was also associated with improved OS is interesting and mirrors that of a recent study in which patients with metachronous disease experienced worse RFS [32]. Of note, the current study excluded patients with extraperitoneal disease as the role of systemic therapy is more established in these patients.

The current study should be interpreted within the context of its limitations, namely its retrospective design. Treatment decisions were not made randomly, and unmeasured differences likely exist between the NAC and SF groups. In preliminary analyses (data not shown), propensity score matching led to similar results but significantly reduced the sample size of the study populations. Other statistical techniques for matching with larger sample sizes could address some of the inherent selection biases. In addition, we were only able to include those patients who successfully completed NAC and underwent surgery. Given the importance of curative-intent surgery on long-term
survival, an intention-to-treat analysis may have led to different findings. Finally, given the study’s multi-institutional and retrospective nature, the NAC regimens, number of courses, surgical procedures, and receipt of postoperative therapies were not standardized.

In conclusion, in this multi-institutional retrospective review of patients with CR-PM undergoing CRS ± HIPEC, patients who received NAC experienced a longer OS compared to those who underwent SF, although NAC was not independently associated with improved RFS or OS after controlling for confounding factors. In light of the recent PRODIGE 7 trial in which the majority of patients received perioperative chemotherapy as well as the current study’s findings, NAC followed by CRS with or without HIPEC appears to be a safe and feasible strategy for CR-PM, aiding in the appropriate selection of patients for aggressive cytoreductive surgery. The development of novel therapies that can successfully downstage CR-PM and facilitate complete cytoreduction is needed.

Author Contributions: Conceptualization, all authors; data curation, all authors; methodology, E.W.B., L.P.S.-K. and J.M.C.; formal analysis, E.W.B.; writing—original draft preparation, E.W.B. and L.P.S.-K.; writing—review and editing, all authors. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest

References
1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
2. Colon Cancer. Version 2.2019. [Internet]. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. 2019. Available online: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (accessed on 1 November 2019).
3. Franko, J.; Shi, Q.; Meyers, J.P.; Maughan, T.S.; Adams, R.; Seymour, M.T.; Saltz, L.; Punt, C.J.; Koopman, M.; Tournigand, C.; et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016, 17, 1709–1719. [CrossRef]
4. Franko, J.; Shi, Q.; Goldman, C.D.; Pockaj, B.A.; Nelson, G.D.; Goldberg, R.M.; Pitot, H.C.; Grothey, A.; Alberts, S.R.; Sargent, D.J. Treatment of Colorectal Peritoneal Carcinomatosis with Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. J. Clin. Oncol. 2011, 30, 263–267. [CrossRef] [PubMed]
5. Klaver, Y.L.B.; Simkens, L.H.J.; Lemmens, V.E.P.P.; Koopman, M.; Teerenstra, S.; Bleichrodt, R.; De Hingh, I.H.; Punt, C. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur. J. Surg. Oncol. 2012, 38, 617–623. [CrossRef]
6. Lieu, C.H.; Renfro, L.A.; De Gramont, A.; Meyers, J.P.; Maughan, T.S.; Seymour, M.T.; Saltz, L.B.; Goldberg, R.M.; Sargent, D.J.; Eckhardt, S.G.; et al. Association of Age with Survival in Patients with Metastatic Colorectal Cancer: Analysis from the ARCAD Clinical Trials Program. J. Clin. Oncol. 2014, 32, 2975–2982. [CrossRef] [PubMed]
7. Glehan, O.; Kwiatkowski, F.; Sugarbaker, P.; Elias, D.; Levine, E.; De Simone, M.; Barone, R.; Yonemura, Y.; Cavaliere, F.; Quenet, F.; et al. Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis from Colorectal Cancer: A Multi-Institutional Study. J. Clin. Oncol. 2004, 22, 3284–3292. [CrossRef] [PubMed]
8. Elias, D.; Lefevre, J.H.; Chevalier, J.; Brouquet, A.; Marchal, F.; Classe, J.-M.; Ferron, G.; Guilloit, J.-M.; Meeus, P.; Goërot, D.; et al. Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia with Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin. J. Clin. Oncol. 2009, 27, 681–685. [CrossRef]
9. Elias, D.; Delperro, J.; Sideris, I.; Benhamou, E.; Pocard, M.; Baton, O.; Giovannini, M.; Lasser, P. Treatment of Peritoneal Carcinomatosis from Colorectal Cancer: Impact of Complete Cytoreductive Surgery and Difficulties in Conducting Randomized Trials. J. Surg. Oncol. 2004, 11, 518–521. [CrossRef]
25. Quenet, F.; Elias, D.; Roca, L.; Goere, D.; Ghouti, L.; Pocard, M.; Facy, O.; Arvieux, C.; Lorimier, G.; Pezet, D.; Dedrick, R.; Flessner, M. Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface Exposure. J. Natl. Cancer Inst. 1997, 89, 480–487. [CrossRef] [PubMed]

26. Devilee, R.A.; Simkens, G.A.; Van Oudheusden, T.R.; Rutten, H.J.; Creemers, G.; Tije, A.J.T.; De Hingh, I.H. Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann. Surg. Oncol. 2016, 23, 2841–2848. [CrossRef]
27. Glehen, O.; Cotte, E.; Schreiber, V.; Vignal, J.; Gilly, F.N. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. *Br. J. Surg.* 2004, 91, 747–754. [CrossRef]

28. Rovers, K.; Bakkers, C.; Simkens, G.; A Burger, J.W.; Nienhuijs, S.W.; Creemers, G.-J.M.; Thijs, A.M.J.; Brandt-Kerkhof, A.R.M.; Madsen, E.V.E.; Ayez, N.; et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: Protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). *BMC Cancer* 2019, 19, 390.

29. Quenet, F.; Goéré, D.; Mehta, S.S.; Roca, L.; Dumont, F.; Hessissen, M.; Saint-Aubert, B.; Elias, M. Results of two Bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. *Ann. Surg.* 2011, 254, 294–301. [CrossRef]

30. Hompes, D.; Aalbers, A.; Boot, H.; Van Velthuysen, M.-L.; Vogel, W.; Prevo, W.; Van Tinteren, H.; Verwaal, V. A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer. *Color. Dis.* 2014, 16, O264–O272. [CrossRef]

31. Vergote, I.; Trope, C.; Amant, F.; Kristensen, G.B.; Ehlen, T.; Johnson, N.; Verheijen, R.H.; Van Der Burg, M.E.; Lacave, A.J.; Panici, P.B.; et al. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIIC or IV Ovarian Cancer. *N. Engl. J. Med.* 2010, 363, 943–953. [CrossRef]

32. Hentzen, J.E.K.R.; Rovers, K.P.; Kuipers, H.; Van Der Plas, W.Y.; Been, L.B.; Hoogwater, F.J.H.; Van Ginkel, R.J.; Hemmer, P.H.J.; Van Dam, G.M.; De Hingh, I.H.J.T.; et al. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study. *Ann. Surg. Oncol.* 2019, 26, 2210–2221. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).